{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T20:48:31Z","timestamp":1781902111573,"version":"3.54.5"},"reference-count":28,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Introduction: Anaemia and bone metabolism alterations are common in inflammatory bowel disease (IBD), which is a heterogeneous group of diseases that include Crohn\u2019s disease (CD) and ulcerative colitis (UC) with a rich intestinal and extraintestinal symptomatology. All these make the diagnostic procedures complicated and difficult. Purpose and scope: The aim of this study was to assess the effect of parenteral iron administration on biomarkers of mineral and bone homeostasis over time. Materials and methods: The study was a single-centre non-randomised prospective study. It was carried out between 2016 and 2020 in a group of patients in the Department of Internal Medicine and Gastroenterology Subunit of Inflammatory Bowel Diseases at the National Institute of Medicine of the Ministry of the Interior and Administration in Warsaw. At the first examination, the baseline disease severity, initial evaluation of anaemia (morphology, iron (Fe), total iron binding capacity (TIBC), ferritin, vitamin B12, folic acid) and bone mineral metabolism including C-reactive protein (CRP), albumins, alkaline phosphatase (ALP), Calcium, osteocalcin, phosphate in serum and in urine, parathyroid hormone (PTH), vitamin D3, fibroblast growth factor (iFGF23) and procollagen type 1N propeptide (P1NP) C-terminal telopeptide (CTX), was initially assessed. On the basis of peripheral blood counts, an appropriate dose of iron (iron derisomaltose or caboxymaltose) was administered. During the subsequent appointments on week 1, 4, and 12 morphology, iron (Fe), total iron binding capacity (TIBC), ferritin, vitamin B12, folic acid, C-reactive protein (CRP), albumins, alkaline phosphatase (ALP), Calcium, osteocalcin, phosphate in serum and in urine, parathyroid hormone (PTH), vitamin D3, fibroblast growth factor (iFGF23) and procollagen type 1N propeptide (P1NP) C-terminal telopeptide (CTX), were evaluated. Results: A total of 56 patients were enrolled into the study: 24 women and 32 men. In the group, 32 patients had Crohn\u2019s disease (CD) and 24 had ulcerative colitis (UC). We found a statistically significant increase in the concentration of albumin (p = 0.031), haemoglobin (p &lt; 0.001), haematocrit (p &lt; 0.001), MCV (p &lt; 0.001), MCHC (p = 0.001), iron (p &lt; 0.001) and ferritin (p &lt; 0.001) after the administration of parenteral iron. The influence of individual iron formulations on the analysed parameters (phosphate concentration in serum and in the urine, iFGF23, P1NP, PTH, vitamin D, haemoglobin and ferritin) was similar. Interestingly, an inverse correlation was found between the concentration of phosphorus in the blood and iFGF23 at certain time-points; however, in the study group they did not significantly affect the disturbances of calcium and phosphate metabolism. Conclusions: In the study group, transient and non-significant disorders of phosphate metabolism were found, which does not constitute a contraindication to treatment with parenteral iron in inflammatory bowel disease patients, which was safe and efficient.<\/jats:p>","DOI":"10.3390\/jpm13030458","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T02:28:17Z","timestamp":1677637697000},"page":"458","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effect of Intravenous Iron Administration on Bone Mineral and Iron Homeostasis in Patients with Inflammatory Bowel Disease\u2014Results of a Prospective Single-Centre Study"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9301-9995","authenticated-orcid":false,"given":"Edyta","family":"Tulewicz-Marti","sequence":"first","affiliation":[{"name":"Clinical Department of Internal Medicine and Gastroenterology with Inflammatory Bowel Disease Subunit, National Medical Institute of the Ministry of the Interior and Administration, 02-507 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Szwarc","sequence":"additional","affiliation":[{"name":"Clinical Department of Internal Medicine and Gastroenterology with Inflammatory Bowel Disease Subunit, National Medical Institute of the Ministry of the Interior and Administration, 02-507 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0413-8520","authenticated-orcid":false,"given":"Martyna","family":"Wi\u0119cek","sequence":"additional","affiliation":[{"name":"Clinical Department of Internal Medicine and Gastroenterology with Inflammatory Bowel Disease Subunit, National Medical Institute of the Ministry of the Interior and Administration, 02-507 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3866-4905","authenticated-orcid":false,"given":"Konrad","family":"Lewandowski","sequence":"additional","affiliation":[{"name":"Clinical Department of Internal Medicine and Gastroenterology with Inflammatory Bowel Disease Subunit, National Medical Institute of the Ministry of the Interior and Administration, 02-507 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Korcz","sequence":"additional","affiliation":[{"name":"Laboratory Diagnostics Department, National Medical Institute of the Ministry of the Interior and Administration, 02-507 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Cicha","sequence":"additional","affiliation":[{"name":"Laboratory Diagnostics Department, National Medical Institute of the Ministry of the Interior and Administration, 02-507 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Rydzewska","sequence":"additional","affiliation":[{"name":"Clinical Department of Internal Medicine and Gastroenterology with Inflammatory Bowel Disease Subunit, National Medical Institute of the Ministry of the Interior and Administration, 02-507 Warsaw, Poland"},{"name":"Collegium Medicum, Jan Kochanowski University, 25-317 Kielce, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease","volume":"10","author":"Harbord","year":"2016","journal-title":"J. Crohns. Colitis."},{"key":"ref_2","first-page":"184","article-title":"Characteristic features of ulcerative colitis withconcomitant primary sclerosing cholangitis","volume":"16","year":"2021","journal-title":"Gastroenterol. Rev. Przegl\u0105d Gastroenterol."},{"key":"ref_3","first-page":"257","article-title":"Guidelines for the management of patients with Crohn\u2019s disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology","volume":"16","author":"Eder","year":"2021","journal-title":"Gastroenterol. Rev. Przegl\u0105d Gastroenterol."},{"key":"ref_4","first-page":"239","article-title":"Management of anemia in inflammatory bowel disease: A challenge in everyday clinical practice","volume":"12","author":"Moniuszko","year":"2017","journal-title":"Prz. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1572-0241.2008.01846.x","article-title":"Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease","volume":"103","author":"Gisbert","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1055\/a-1283-6832","article-title":"Iron deficiency, depression, and fatigue in inflammatory bowel diseases. Eisenmangel, Depression und Ersch\u00f6pfung bei CED","volume":"58","author":"Jimenez","year":"2020","journal-title":"Z Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/01.MIB.0000196646.64615.db","article-title":"Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients","volume":"12","author":"Wells","year":"2006","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/ecco-jcc\/jju009","article-title":"European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases","volume":"9","author":"Dignass","year":"2015","journal-title":"J. Crohns. Colitis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1080\/17474124.2021.1900730","article-title":"Iron deficiency anemia in IBD: An overlooked comorbidity","volume":"15","author":"Shah","year":"2021","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"200","DOI":"10.23736\/S1121-421X.19.02572-8","article-title":"Oral iron supplementation with Feralgine\u00ae in inflammatory bowel disease: A retrospective observational study","volume":"65","author":"Vernero","year":"2019","journal-title":"Minerva Gastroenterol. Dietol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11739-018-1993-9","article-title":"Safety and efficacy of sucrosomial iron in inflammatory bowel disease patients with iron deficiency anemia","volume":"14","author":"Abbati","year":"2019","journal-title":"Intern. Emerg. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10620-022-07599-1","article-title":"Ironing It All Out: A Comprehensive Review of Iron Deficiency Anemia in Inflammatory Bowel Disease","volume":"68","author":"Maas","year":"2022","journal-title":"Dig. Dis. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/MNH.0000000000000329","article-title":"Iron-induced hypophosphatemia: An emerging complication","volume":"26","author":"Zoller","year":"2017","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"R147","DOI":"10.1186\/cc9215","article-title":"Treatment of hypophosphatemia in the intensive care unit: A review","volume":"14","author":"Geerse","year":"2010","journal-title":"Crit. Care"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s00467-012-2175-z","article-title":"Phosphate homeostasis and its role in bone","volume":"27","author":"Alon","year":"2012","journal-title":"Pediatr. Nephrol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1155\/2003\/391308","article-title":"The frequency of vitamin D deficiency in adults with Crohn\u2019s disease","volume":"17","author":"Siffledeen","year":"2003","journal-title":"Can. J. Gastroenterol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00054725-200405000-00007","article-title":"Bones and Crohn\u2019s: Risk factors associated with low bone mineral density in patients with Crohn\u2019s disease","volume":"10","author":"Siffledeen","year":"2004","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1590\/S0004-28032015000400003","article-title":"Lower levels of vitamin D correlate with clinical disease activity and quality of life in Inflammatory Bowel Disease","volume":"52","author":"Castro","year":"2015","journal-title":"Arq. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.3748\/wjg.v24.i29.3293","article-title":"Fatigue is not associated with vitamin D deficiency in inflammatory bowel disease patients","volume":"24","author":"Frigstad","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1080\/003655202753416876","article-title":"Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease","volume":"37","author":"Jahnsen","year":"2021","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1111\/bcp.14643","article-title":"Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis","volume":"87","author":"Schaefer","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/bcp.13189","article-title":"Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions","volume":"83","author":"Bager","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1080\/00365521.2018.1498914","article-title":"Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice","volume":"53","author":"Stein","year":"2018","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/ecco-jcc\/jjy042","article-title":"Safety and Efficacy of Ferric Carboxymaltose in the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease, in Routine Daily Practice","volume":"12","author":"Stein","year":"2018","journal-title":"J. Crohns. Colitis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1080\/00365521.2016.1196496","article-title":"High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23","volume":"51","author":"Dahlerup","year":"2016","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis","volume":"19","author":"Shimada","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2019.22450","article-title":"Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials","volume":"323","author":"Wolf","year":"2020","journal-title":"JAMA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.3748\/wjg.v27.i17.2039","article-title":"Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact","volume":"27","author":"Detlie","year":"2021","journal-title":"World J. Gastroenterol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/3\/458\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:44:45Z","timestamp":1760121885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/3\/458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["jpm13030458"],"URL":"https:\/\/doi.org\/10.3390\/jpm13030458","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,28]]}}}